Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: A 24-wk randomized, controlled, double-blind trial

International Journal of Neuropsychopharmacology

Volumn 16, Issue 10, 2013, Pages 2219-2234

  Corruble, Emmanuelle ^a   De Bodinat, Christian ^b   Belaïdi, Carole ^b   Goodwin, Guy M ^c   Burrows, G ^d   Lopes Rocha, F ^d   Bakish, D ^d   Emsley, R ^d   Avedisova, A ^d   Hale, A ^d  

^a BICÊTRE HOSPITAL   (France)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c WARNEFORD HOSPITAL   (United Kingdom)

^d NONE

Author keywords

Agomelatine; emotional blunting; escitalopram; subjective sleep

Indexed keywords

AGOMELATINE; ANXIOLYTIC AGENT; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ABNORMAL DREAMING; ADULT; AGED; AGITATION; ANXIETY DISORDER; ARTHRALGIA; BACKACHE; BRONCHITIS; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DAYTIME SOMNOLENCE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EMOTIONAL DISORDER; FATIGUE; FEMALE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INFECTION; INFESTATION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL PATIENT; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; OXFORD QUESTIONNAIRE; PATIENT SATISFACTION; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SINUSITIS; SLEEP; SLEEP DISORDER; SLEEP QUALITY; SLEEP WAKING CYCLE; SOMNOLENCE; SORE THROAT; SUICIDE ATTEMPT; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WAKEFULNESS;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SLEEP; TIME FACTORS; TREATMENT OUTCOME; WAKEFULNESS;

EID: 84885577161     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000679     Document Type: Conference Paper

References (24)

1. Armitage R (2007) Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand (Suppl.) 115:104-115
2. Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Leger D, Linkowski P, Mendelson WB, Racagni G, Saletu B, Sharpley AL, Turek F, Van Cauter E, Mendlewicz J (2000) Depression and sleep disorders: Clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology 42:107-119
3. Colonna L, Andersen HF, Reines EH (2005) A randomized, double-blind, 24-week study of escitalopram (10 mg/day) vs. citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 21:1659-1668
4. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev Drug Discov 9:628-642
5. Goodwin GM (2009) Clinical studies on the efficacy of agomelatine on depressive symptoms. CNS Drugs 23 (Suppl. 2):35-39
6. Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338, pp 217-222. National Institute of Mental Health, Rockville, MD.
7. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V (2010) Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: A randomized, double-blind study. Int Clin Psychopharmacol 25:305-314
8. Harmer CJ, de BC, Dawson GR, Dourish CT, Waldenmaier L, Adams S, Cowen PJ, Goodwin GM (2011) Agomelatine facilitates positive vs. negative affective processing in healthy volunteer models. J Psychopharmacol 25:1159-1167
9. Hindmarch I (1975) A 1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour. Arzneimittelforschung 25:1836-1839
10. Iovieno N, van NA, Clain A, Baer L, Nierenberg AA (2011) Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 28:137-144
11. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Bayle FJ (2010) Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J Clin Psychiatry 71:109-120
12. Kennedy SH, Rizvi SJ (2010) Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 24:479-499
13. Kennedy SH, Rizvi S, Fulton K, Rasmussen J (2008) A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 28:329-333
14. Lemoine P, Guilleminault CAE (2007) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, DoubleBlind comparison with venlafaxine. J Clin Psychiatry 68:1723-1732
15. Menza M, Marin H, Opper RS (2003) Residual symptoms in depression: Can treatment be symptom-specific? J Clin Psychiatry 64:516-523
16. Montejo AL, Prieto N, Terleira A, Matias J, Alonso S, Paniagua G, Naval S, Parra DG, Gabriel C, Mocaer E, Portoles A (2010) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 24:111-120
17. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004) Absence of discontinuation symptoms with agomelatine and occurrence of discontinuationsymptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271-280
18. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR.D report. Psychol Med 40:41-50
19. Olie JP, Kasper S (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673
20. Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, Manber R (2002) Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 5:147-151
21. Price J, Cole V, Goodwin GM (2009) Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 195:211-217
22. Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, Lofaso F, Guilleminault C (2007) Major depressive disorder, sleep EEG and agomelatine: An open-label study. Int J Neuropsychopharmacol 10:691-696
23. Quera-Salva MA, Lemoine P, Guilleminault C (2010) Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 25:222-229
24. Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le GS, Laredo J, Guilleminault C (2011) Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 26:252-262